中生北控生物科技股份有限公司

BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION*

(Incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

INTERIM RESULTS ANNOUNCEMENT FOR THE THREE MONTHS AND SIX MONTHS ENDED 30 JUNE 2008

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (THE "GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

The principal means of information dissemination on GEM is publication on the internet website operated by the Stock Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed companies.

The Stock Exchange takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors (the "Directors") of Biosino Bio-Technology and Science Incorporation (the "Company") collectively and individually accept full responsibilities, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

* *For identification purposes only*

UNAUDITED CONSOLIDATED INTERIM RESULTS

The Board of Directors (the "Board") of the Company announced the unaudited consolidated results of the Group for the three months and six months ended 30 June 2008 and the unaudited condensed consolidated balance sheet of the Group as at 30 June 2008, together with the comparative figures in 2007, as follows:

CONDENSED CONSOLIDATED INCOME STATEMENT

For the three months and six months ended 30 June 2008

		Three months ended 30 June		**Six months ended 30 June**	
		2008	2007	**2008**	2007
		Unaudited	Unaudited	**Unaudited**	Unaudited
	Notes	***RMB'000***	*RMB'000*	***RMB'000***	*RMB'000*
REVENUE	*2, 3*	**59,924**	47,188	**104,333**	83,652
Cost of sales		**(18,948)**	(16,472)	**(34,211)**	(29,318)
Gross profit		**40,976**	30,716	**70,122**	54,334
Other income and gain		**4,315**	2,033	**3,471**	3,122
Gain on disposal of financial assets at fair value through profit or loss		**–**	–	**1,338**	566
Selling and distribution expenses		**(13,935)**	(11,322)	**(25,904)**	(18,582)
Administrative expenses		**(15,546)**	(11,227)	**(25,268)**	(19,776)
Research and development expenses		**(1,278)**	(2,029)	**(4,676)**	(5,018)
Other operating expenses		**(2,395)**	(161)	**(2,395)**	(556)
PROFIT FROM OPERATING ACTIVITIES	*4*	**12,137**	8,010	**16,688**	14,090
Finance costs	*5*	**(2,830)**	(1,390)	**(2,977)**	(2,732)
Share of loss of a jointy-controlled entity		**(29)**	–	**(268)**	–
PROFIT BEFORE TAX		**9,278**	6,620	**13,443**	11,358
Tax	*6*	**(2,343)**	(1,830)	**(3,777)**	(3,294)
PROFIT FOR THE PERIOD		**6,935**	4,790	**9,666**	8,064
Attributable to:					
Shareholders of the Company		**6,249**	4,180	**8,982**	7,182
Minority interests		**686**	610	**684**	882
		6,935	4,790	**9,666**	8,064
EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	*7*				
– Basic (RMB)		**0.062**	0.042	**0.090**	0.072
– Diluted		**N/A**	N/A	**N/A**	N/A

CONDENSED CONSOLIDATED BALANCE SHEET

As at 30 June 2008

	Notes	30 June 2008 Unaudited RMB'000	31 December 2007 Audited RMB'000
ASSETS			
Non-current assets:			
Property, plant and equipment		**117,395**	118,998
Prepaid land premiums		**7,321**	7,470
Goodwill		**470**	470
Other intangible assets		**2,019**	2,450
Interest in a jointly-controlled entity		**–**	268
Trade and bills receivables	*9*	**1,966**	1,966
Long-term deposits		**1,742**	1,751
Total non-current assets		**130,913**	133,373
Current assets:			
Prepaid land premiums		**178**	177
Inventories		**27,565**	24,749
Trade and bills receivables	*9*	**45,298**	33,716
Prepayments, deposits and other receivables		**9,000**	7,936
Financial assets at fair value through profit or loss		**33,538**	–
Cash and cash equivalents		**119,613**	148,721
Total current assets		**235,192**	215,299
TOTAL ASSETS		**366,105**	348,672

	Notes	**30 June 2008 Unaudited** *RMB'000*	31 December 2007 Audited *RMB'000*
EQUITY AND LIABILITIES			
Equity attributable to shareholders of the Company:			
Issued capital	*10*	**100,018**	100,018
Reserves		**79,989**	71,007
Proposed final dividend		**–**	10,002
		180,007	181,027
Minority interests		**23,848**	21,965
TOTAL EQUITY		**203,855**	202,992
Non-current liabilities:			
Bank borrowings		**40,100**	40,000
Deferred income		**12,441**	9,481
Other payables and accruals		**1,800**	1,800
Total non-current liabilities		**54,341**	51,281
Current liabilities:			
Trade payables	*11*	**10,453**	7,364
Other payables and accruals		**40,407**	31,087
Taxes payable		**7,049**	6,156
Bank borrowings		**50,000**	49,792
Total current liabilities		**107,909**	94,399
TOTAL LIABILITIES		**162,250**	145,680
TOTAL EQUITY AND LIABILITIES		**366,105**	348,672

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2008

	Attributable to shareholders of the Company							
	Issued share capital	**Capital reserves#**	**Statutory reserves**	**Retained Profits**	**Proposed final dividend**	**Total**	**Minority interests**	**Total equity**
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
At 1 January 2007	100,018	30,309	20,179	10,344	10,002	170,852	18,872	189,724
Profit for the period and total income and expense for the period	–	–	–	7,182	–	7,182	882	8,064
Final 2006 dividend declared	–	–	–	–	(10,002)	(10,002)	–	(10,002)
Acquisition of an interest in a subsidiary	–	–	–	–	–	–	574	574
At 30 June 2007	100,018	30,309	20,179	17,526	–	168,032	20,328	188,360
At 1 January 2008	100,018	30,557	22,531	17,919	10,002	181,027	21,965	202,992
Profit for the period and total income and expense for the period	–	–	–	8,982	–	8,982	684	9,666
Final 2007 dividend declared	–	–	–	–	(10,002)	(10,002)	–	(10,002)
Capital contribution from a minority shareholder	–	–	–	–	–	–	1,199	1,199
At 30 June 2008	100,018	30,557†	22,531†	26,901†	–	180,007	23,848	203,855

\# The capital reserves of the Group include non-distributable reserves of the Company and its subsidiaries created in accordance with the accounting and financial regulations of the PRC.

† These reserve accounts comprise the consolidated reserves of RMB79,989,000 and RMB71,007,000 in the consolidated balance sheet as at 30 June 2008 and 31 December 2007, respectively.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

For the six months ended 30 June 2008

	Six months ended 30 June	
	2008	2007
	Unaudited	Unaudited
	RMB'000	*RMB'000*
Net cash inflow from operating activities	**4,489**	7,498
Net cash outflow from investing activities	**(34,013)**	(5,309)
Net cash inflow/(outflow) from financing activities	**416**	(7,522)
Decrease in cash and cash equivalents	**(29,108)**	(5,333)
Cash and cash equivalents at beginning of period	**148,721**	154,580
Cash and cash equivalents at end of period	**119,613**	149,247

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements for the three months and six months ended 30 June 2008 have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants and accounting principles generally accepted in Hong Kong. The accounting policies and basis of preparation used in the preparation of the unaudited condensed consolidated financial statements are consistent with those used in the Company's audited financial statements for the year ended 31 December 2007.

2. SEGMENT INFORMATION

Segment information is presented by way of the Group's primary segment reporting basis, by business segment. In determining the Group's geographical segments, revenues are attributed to the segments based on the location of the customers, and assets are attributed to the segments based on the location of the assets. No further geographical segment information is presented as over 90% of the Group's revenue is derived from customers based in Mainland China, and all of the Group's assets are located in Mainland China.

The Group's operating businesses are structured and managed separately according to the nature of their operations and the products they provide. Each of the Group's business segments represents a strategic business unit that offers products which are subject to risks and returns that are different from those of the other business segment. Particulars of the business segments are summarised as follows:

(i) the in-vitro diagnostic reagent products segment manufactures, sells and distributes a variety of mono/double diagnostic reagent products; and

(ii) the pharmaceutical products segment manufactures, sells and distributes pharmaceutical products.

2. **SEGMENT INFORMATION** *(Continued)*

The following tables present revenue and results for the Group's business segments for each of the six months ended 30 June 2008 and 2007:

Six months ended 30 June 2008

	In-virto diagnostic reagent products Unaudited *RMB'000*	Pharma-ceutical products Unaudited *RMB'000*	Eliminations Unaudited *RMB'000*	Total Unaudited *RMB'000*
Segment revenue:				
Sales to external customers	**70,689**	**33,644**	**–**	**104,333**
Other income	**3,784**	**–**	**–**	**3,784**
Total	**74,473**	**33,644**	**–**	**108,117**
Segment results	**10,652**	**5,011**	**–**	**15,663**
Interest income				**1,025**
Profit from operating activities				**16,688**
Finance costs				**(2,977)**
Share of loss of a jointly-controlled entity	**(268)**	**–**	**–**	**(268)**
Profit before tax				**13,443**
Tax				**(3,777)**
Profit for the period				**9,666**

2. **SEGMENT INFORMATION** *(Continued)*

Six months ended 30 June 2007

	In-virto diagnostic reagent products Unaudited *RMB'000*	Pharma-ceutical products Unaudited *RMB'000*	Eliminations Unaudited *RMB'000*	Total Unaudited *RMB'000*
Segment revenue:				
Sales to external customers	54,026	29,626	–	83,652
Other income	2,996	–	–	2,996
Total	57,022	29,626	–	86,648
Segment results	9,281	4,117	–	13,398
Interest income				692
Profit from operating activities				14,090
Finance costs				(2,732)
Profit before tax				11,358
Tax				(3,294)
Profit for the period				8,064

3. **REVENUE**

Revenue, which is also the Group's turnover, represents the net invoiced value of goods sold, net of value-added tax and government surcharges, and after allowances for the goods returned and trade discounts.

An analysis of the Group's revenue for the three months and six months ended 30 June 2008 is as follows:

	Three months ended 30 June		**Six months ended 30 June**	
	2008 **Unaudited** ***RMB'000***	2007 Unaudited *RMB'000*	**2008** **Unaudited** ***RMB'000***	2007 Unaudited *RMB'000*
Sale of in-vitro diagnostic reagent products	**41,639**	30,774	**70,689**	54,026
Sale of pharmaceutical products	**18,285**	16,414	**33,644**	29,626
	59,924	47,188	**104,333**	83,652

4. PROFIT FROM OPERATING ACTIVITIES

The Group's profit from operating activities is arrived at after charging:

	Three months ended 30 June		**Six months ended 30 June**	
	2008	2007	**2008**	2007
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Depreciation	**3,534**	2,551	**6,210**	4,973
Amortisation of know-how	**220**	108	**457**	214
Amortisation of prepaid land premiums	**46**	39	**92**	77

5. FINANCE COSTS

	Three months ended 30 June		**Six months ended 30 June**	
	2008	2007	**2008**	2007
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Interests on bank loans	**2,830**	1,390	**2,977**	2,732

6. TAX

No provision for Hong Kong profits tax has been made as the Group has not generated any assessable profits in Hong Kong during the six months ended 30 June 2008 (2007: Nil). Taxes on profits assessable in Mainland China, where the Group operates, have been calculated at the rates of tax prevailing in Mainland China, based on existing legislation, interpretations and practices in respect thereof. According to the relevant PRC income tax law, the Company and certain of its subsidiaries, being registered as new and high technology enterprises in Beijing, are entitled to concessionary income tax rates of 15% and 7.5%, where appropriate, which have been applied for both periods.

	Three months ended 30 June		**Six months ended 30 June**	
	2008	2007	**2008**	2007
	Unaudited	Unaudited	**Unaudited**	Unaudited
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Current – Mainland, the PRC	**2,343**	1,830	**3,777**	3,294

7. EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic earnings per share for the three months and six months ended 30 June 2008 is based on the unaudited profit attributable to shareholders of the Company for the period and the weighted average of 100,017,528 (2007: 100,017,528) registered shares in issue during the period.

No diluted earnings per share have been presented as there was no diluting event existed during the three months and six months ended 30 June 2008 (2007: Nil).

8. INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2008 (2007: Nil).

9. TRADE AND BILLS RECEIVABLES

Except for certain established customers of the Group for several instalment sales contracts entered into with payment terms ranging from two to four years, the credit period of the Group granted to its customers generally for a period ranging from 60 days to 90 days. The Group closely monitors overdue balances, and impairment is made when it is considered that amounts due may not be recovered. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. Trade and bills receivables are interest-free.

An aged analysis of the trade and bills receivables of the Group as at the balance sheet date based on invoice date, are as follows:

	30 June 2008 Unaudited ***RMB'000***	31 December 2007 Audited *RMB'000*
Within 3 months	**39,453**	25,917
4 to 6 months	**3,604**	4,938
7 to 12 months	**1,820**	5,854
1 to 2 years	**2,940**	1,016
Over 2 years	**1,170**	1,506
	48,987	39,231
Less: Impairment	**(1,723)**	(3,549)
	47,264	35,682
Less: Portion classified as current assets	**(45,298)**	(33,716)
Non-current portion	**1,966**	1,966

The carrying amounts of the trade and bills receivables approximate to their fair values.

10. SHARE CAPITAL

	30 June 2008 Unaudited ***RMB'000***	31 December 2007 Audited *RMB'000*
Registered, issued and fully paid:		
67,017,528 domestic shares of RMB1 each	**67,018**	67,018
33,000,000 H shares of RMB1 each	**33,000**	33,000
	100,018	100,018

11. TRADE PAYABLES

An aged analysis of trade payables of the Group as at the balance sheet date, based on the invoice date, is as follows:

	30 June 2008 Unaudited ***RMB'000***	31 December 2007 Audited *RMB'000*
Within 3 months	**8,003**	6,767
4 to 6 months	**1,912**	–
7 to 12 months	**171**	353
1 to 2 years	**291**	179
Over 2 years	**76**	65
	10,453	7,364

The trade payables are non-interest-bearing and are normally settled on credit terms ranging from 30 days to 90 days.

12. CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2008 (2007: Nil).

13. COMMITMENTS

(a) The Group had the following capital commitments in respect of plant and machinery at the balance sheet date:

	30 June 2008 Unaudited *RMB'000*	31 December 2007 Audited *RMB'000*
Authorised, but not contracted for	**520**	592
Contracted, but not provided for	**7,630**	3,073
	8,150	3,665

(b) Pursuant to a research and development co-operation agreement (the "Research and Development Co-operation Agreement") dated 9 August 2004 entered into between the Group and the IBP, a shareholder of the Company, both parties will jointly engage in a pre-clinical research project for the development of a chemical drug, namely, Alprostadil for Injection. Upon completion of such pre-clinical research, the Group will have the right to obtain the ownership of the relevant clinical testing certificate and the production licence to be issued thereafter by the State Food and Drug Administration of the PRC, while the Group will have to complete the co-development of the pre-clinical research according to the Research and Development Co-operation Agreement. The assessed market value of the clinical research rights is subject to a cap of RMB5,000,000. Therefore, the maximum amount of consideration that the Group would pay to the IBP to acquire the clinical research rights will be RMB2,500,000.

(c) On 9 December 2004, the IBP and the Group entered into an exclusive technology licensing agreement (the "Licensing Agreement") in regard to the production of diagnostic reagents by employing the technologies owned by the IBP (the "Reagent Technologies"). Pursuant to the Licensing Agreement, the Company is required to pay a fee of RMB500,000 per annum to the IBP for 20 years, commencing on the effective date of the Licensing Agreement. In addition, the IBP confirmed that it would not pursue any legal or economic obligations against the Company, which had used the Reagent Technologies in prior years. In the opinion of the directors, the technical service fee was determined based on negotiation and by reference to the valuation of the Reagent Technologies performed by an independent PRC asset appraisal valuer in August 2000.

14. RELATED PARTY TRANSACTIONS

(a) The Group had the following material transactions with related parties during the period:

		Six months ended 30 June	
		2008	2007
		Unaudited	Unaudited
	Note	***RMB'000***	*RMB'000*
Technical service fee paid	*(i)*	**250**	250

Note:

(i) Details of the technical service fee paid are set out in note 13(c).

(b) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2008	2007
	Unaudited	Unaudited
	RMB'000	*RMB'000*
Short term employee benefits	**3,464**	3,359
Post-employment benefits	**–**	–
Total compensation paid to key management personnel	**3,464**	3,359

The directors are of the opinion that the above transactions were conducted in the ordinary course of business of the Group.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review for the first half of 2008

The market for our products was further expanded in the first half of the year because of the persistent growth in the Chinese domestic medical sector, together with the accelerated improvement to the quality of certain products, the enhanced proprietary innovation awareness and capability of many tertiary-level hospitals, and the stepped up partnership between the Group and hospitals following the implementation of the "863 Program" by the Group. With respect to sales, the Group adopted timely and corresponding initiatives to the natural disasters and to the changes in economic situation by adjusting its sales strategies. As a result, the Group's business operations achieved a rapid development momentum.

The additional resources committed to research and development over the past year have begun to reap the fruits. In the first half of the year, the Group applied another two new products for approval. Relevant processes prior to application for approval were completed for several new products and upgrade products respectively, and the application for approval and registration are expected to be completed within this year.

Financial Review for the first half of 2008

Revenue for the six months ended 30 June 2008 was approximately RMB104 million, representing an increase of 24.7% as compared with approximately RMB83.65 million for the corresponding period last year. For the revenue of this period, approximately RMB70.69 million was generated from the sale of in-vitro diagnostic reagent products, accounting for 67.8% of the Group's total revenue and representing an increase of 30.8% as compared with RMB54.03 million for the corresponding period last year. As for pharmaceutical products, the revenue from the sale of Lumbrokinase capsules was RMB33.64 million, accounting for 32.2% of the Group's total revenue and representing an increase of 13.6% as compared with RMB29.62 million for the corresponding period last year.

For the six months ended 30 June 2008, profit from operating activities amounted to RMB16.69 million, representing an increase of 18.5% over the corresponding period last year.

Profit attributable to shareholders for the six months ended 30 June 2008 was RMB8.98 million, representing an increase of approximately 25.1% as compared with RMB7.18 million for the corresponding period last year. Such increase was mainly attributable to the growth in the Group's principal business.

Prospect and Outlook

Looking forward, the Group will continue to make efforts in the establishment of the technological innovation system, the reference system and the industry standard system for the in-vitro diagnostic industry. By inputting further effort in the research and development of new products in order to enhance the proprietary innovation capability and core competitiveness. The Group will strive to expand the product chain and move into the new sectors for diagnostic products for immunology while working to strengthen diagnostic products for clinical biochemistry. It is anticipated that the Group will have several additional new in-vitro diagnostic products and pharmaceuticals by the end of the year, which will facilitate the Group's sustainable development.

Meanwhile, the Board believes the loosened State's policy for the medical sector and market growth will provide development opportunities for the Group. The Group will seize these opportunities and to carry out merger and acquisition aggressively with caution within its principal business portfolio for exploring new areas; continue to reinforce the establishment of the market network and establish a competitive industry system for maintaining its sustainable development in order to contribute to maximizing shareholders' interest.

OTHER INFORMATION

Purchase, Sale or Redemption of the Company’s Listed Securities

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities during the six months ended 30 June 2008.

Compliance Adviser’s Interest

As updated and notified by the Company’s compliance adviser, Guangdong Securities Limited (the “Compliance Adviser”), none of the Compliance Adviser, or its directors, employees or associates (as defined under the GEM Listing Rules) had any interest in the share capital of the Company or any member of the Group (including options or rights to subscribe for such securities) as at 30 June 2008 pursuant to Rule 6A.32 of the GEM Listing Rules.

Pursuant to an agreement dated 24 June 2008 entered into between the Company and the Compliance Adviser, the Compliance Adviser will receive a fee for acting as the Company’s compliance adviser for the period from 28 June 2008 to 31 March 2009 or until the agreement is terminated in accordance with the terms and conditions set out therein.

Securities Transactions by Directors

During the period under review, the Company has adopted the standards set out in Rules 5.48 to 5.67 of the GEM Listing Rules as the code of conduct regarding the Directors’ securities transactions in securities of the Company. Having made specific enquiry to all Directors and the Company was not aware of any non-compliance with the required standards of dealings its code of conduct regarding securities transactions by Directors.

Audit Committee

The Company has established an audit committee with written terms of reference in compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit committee’s primary duties are the review and supervision of the Company’s financial reporting procedures and internal control system. The Group’s unaudited condensed consolidated financial statements for the period have been reviewed by the audit committee with the three independent non-executive directors of the Company, namely Dr. Rao Yi, Dr. Hua Sheng and Mr. Chan Yiu Kwong.

Code on Corporate Governance Practices

The Company always puts strong emphasis on the superiority, steadiness and rationality of corporate governance. Except for the deviation that Mr. Wu Lebin assumes the role of both the chairman of the Board and the president of the Company, the Company has complied with all the code provisions in the Code on Corporate Governance Practices as set out in Appendix 15 of the GEM Listing Rules (the "Code") for the period ended 30 June 2008 by establishing a formal and transparent procedures to protect and maximise the interests of shareholders during the year under review, The Board is of the view that it is in the best interests of the Group to have Mr. Wu, who have vast and solid experience in the medical industry to perform the dual role so that the Board can have the benefits of a chairman who is knowledgeable about the business of the Group and is most capable to guide and brief the Board in a timely manner on pertinent issues.

By order of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman

Beijing, the PRC, 8 August 2008

As at the date of this announcement, the Board comprises:

Chairman and Executive Director
Mr. Wu Lebin *（吳樂斌先生）*

Vice Chairman and Non-executive Directors
Mr. Zhang Yong *（張勇先生）* and Dr. Gao Guang Xia *（高光俠博士）*

Executive Directors
Dr. Wang Lin *（王琳博士）* and Mr. Hou Quanmin *（侯全民先生）*

Non-executive Directors
Ms. Qin Xuemin *（秦學民女士）*, Mr. Rong Yang *（榮洋先生）*, Mr. Wang Fu Gen *（王福根先生）* and Ms. Yu Xiaomin *（郁小民女士）*

Independent non-executive Directors
Dr. Rao Yi *（饒毅博士）*, Dr. Hua Sheng *（華生博士）* and Mr. Chan Yiu Kwong *（陳耀光先生）*

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkgem.com and the Company's website at www.zhongsheng.com.cn for at least 7 days from the date of its posting.